Pietro Scalfaro has joined the board of diagnostics technology development firm Biocartis, the company said this week.
Scalfaro is chief project officer at the Debiopharm Group, which develops biologics and small-molecule drugs.
Debiopharm was one of two new investors in Biocartis in a Series B financing round announced this week that raised €30 million ($40 million). Johnson & Johnson Development was the other new investor. The firm will use the proceeds to further build out the first version of its proprietary platform, the company said in a statement.
Biocartis, founded in 2007 and based in Lausanne, Switzerland, has licensed and developed new technologies to build a "broadly applicable new diagnostics platform for low to highly multiplexed detection, quantification, and amplification of molecular-based biomarkers, including nucleic acids, proteins, and small molecules," the company said in a statement.